A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer

Authors :: Meyerhardt, Jeffrey A
Grady, Michele M
Lowe, Jamie N
Gargano, Michele A
Huhn, Richard D
Braun, Ada H
Source :: Meyerhardt, Jeffrey A, Michele M Grady, Jamie N Lowe, Michele A Gargano, Richard D Huhn, and Ada H Braun. 2014. “A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer.” Journal for Immunotherapy of Cancer 2 (Suppl 3): P71. doi:10.1186/2051-1426-2-S3-P71. http://dx.doi.org/10.1186/2051-1426-2-S3-P71.
Publication Year :: 2014
Publisher :: BioMed Central, 2014.

Language :: English
ISSN :: 20511426
Database :: Digital Access to Scholarship at Harvard (DASH)
Journal :: Meyerhardt, Jeffrey A, Michele M Grady, Jamie N Lowe, Michele A Gargano, Richard D Huhn, and Ada H Braun. 2014. “A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer.” Journal for Immunotherapy of Cancer 2 (Suppl 3): P71. doi:10.1186/2051-1426-2-S3-P71. http://dx.doi.org/10.1186/2051-1426-2-S3-P71.
Accession number :: edshld.1.13890586
Document Type :: Other
Full Text :: https://doi.org/10.1186/2051-1426-2-S3-P71

Full Text Access

Tools